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Abstract
Purpose—Ultrasonic propulsion is a new technology using focused ultrasound energy applied 
transcutaneously to reposition kidney stones. We report the findings from the first human 
investigational trial of ultrasonic propulsion toward the applications of expelling small stones and 
dislodging large obstructing stones.
Materials and Methods—Subjects underwent ultrasonic propulsion either awake without 
sedation in clinic or during ureteroscopy while anesthetized. Ultrasound imaging and a pain 
questionnaire were completed before, during, and after propulsion.
The primary outcome was to reposition stones in the collecting system. Secondary outcomes 
included safety, controllable movement of stones, and movement of stones < 5 mm and ≥ 5 mm. 
Adverse events were assessed weekly for 3 weeks.
Results—Kidney stones were repositioned in 14 of 15 subjects. Of the 43 targets, 28 (65%) 
showed some level of movement while 13 (30%) were displaced > 3 mm to a new location. 
Discomfort during the procedure was rare, mild, brief, and self-limited. Stones were moved in a 
controlled direction with over 30 fragments being passed by 4 of 6 subjects who previously had a 
lithotripsy procedure. The largest stone moved was 10 mm. One patient experienced pain relief 
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during treatment of a large stone at the UPJ. In 4 subjects a seemingly large stone was determined 
to be a cluster of small passable stones once moved.
Conclusions—Ultrasonic propulsion was able to successfully reposition stones and facilitate 
passage of fragments in humans with no adverse events associated with the investigational 
procedure.
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INTRODUCTION
The prevalence of kidney stones continues to increase and is estimated to affect nearly 9% of 
the US population.1 The unpredictability of stone movement and resultant pain cause 
anticipatory fear in many individuals with kidney stones, and it is not uncommon for a single 
stone episode to result in multiple emergency room visits and at least one surgical 
procedure.2 The annual medical expenditures of urinary stone disease has soared to $10 
billion making it one of the most costly urologic conditions.3 While surgical treatment of 
kidney stones has evolved from large-incision surgery to noninvasive procedures, the current 
treatment options commonly leave behind residual stone fragments.4 Studies have shown 
that while most residual fragments will pass, others may grow, and in approximately 
20%-40% of patients, lead to symptomatic events such as pain, emergency room visits, or 
additional procedures.5-9
Ultrasonic propulsion is a new technology developed to reposition kidney stones and 
facilitate passage using focused ultrasound energy applied transcutaneously.10-14 The 
proposed use is to expel stone fragments while they are small and passable. Other uses 
include moving larger stones back into the kidney to relieve acute renal obstruction and pain; 
and help small newly formed, or de novo, stones pass naturally under controlled conditions, 
rather than waiting for an unpredictable event or until stone growth requires surgery.
The ultrasonic propulsion technology has evolved over 5 years to a clinical prototype 
device.10-14 Safety and effectiveness have been demonstrated in a porcine model, and an 
Investigational Device Exemption (IDE) was obtained from the US Food and Drug 
Administration (FDA) to test the device in humans.15,16 Herein we report the findings of the 
first-in-human clinical trial of ultrasonic propulsion.
MATERIALS AND METHODS
A single-center, first in human, feasibility study was conducted at the University of 
Washington (UW) with approval from the UW Institutional Review Board and the US FDA 
through an IDE.
Study Objectives
The primary goal was to demonstrate the ability to reposition stones within the human 
collecting system. Secondary goals included to: (a) demonstrate the ability to move stones in 
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a controlled direction, (b) demonstrate the ability to move both small (< 5mm) and larger (≥ 
5mm) stones, and (c) determine any safety issues or discomfort associated with the 
investigational procedure. We further investigated the potential impact of stone size, stone 
location, patient position, treatment voltage, and stone type (de novo vs. fragment) on stone 
motion.
Investigational Device
The investigational system is essentially a diagnostic ultrasound platform capable of 
emitting longer-duration, slightly higher-amplitude, focused pulses (VDAS, Verasonics Inc, 
Redmond, WA). A graphical user interface and ultrasound image is displayed on a 
touchscreen monitor.
The custom-derived Push sequence was developed and optimized to work on the same 
diagnostic probe (HDI C5-2 curvilinear array, Philips Ultrasound, Andover, MA) as is used 
to image the kidney. The operator activates a single Push either by touching the stone on the 
touchscreen or clicking the mouse with the cursor on the stone. The Push sequence occurs 
between 2 B-mode imaging frames, giving real-time imaging feedback of stone motion. The 
Push can be applied to any location within the image. Two Push voltage settings are 
available: low (50V) and high (90V). Low power is used at shallow depths where there is 
less acoustic attenuation, and high power is employed at greater depths (≥ 7cm).
Study Population
Individuals presenting to a single provider's UW Urology clinic from November 2013 until 
October 2014 were screened. Inclusion and exclusion criteria are listed in Table 1.
Because the ultimate application of this technology has a broad scope of use, restrictions on 
enrollment criteria were minimized. Group 1 (postlithotripsy) included subjects that had 
undergone a lithotripsy procedure within the last year with small (< 5mm) residual 
fragments. Group 2 included subjects with small (< 5mm) de novo stones. Group 3 included 
subjects with large (≥ 5mm) stones who would undergo a planned ureteroscopy the same 
day following ultrasonic propulsion. Group 4 included subjects with large (≥ 5mm) stones 
who would undergo simultaneous ultrasonic propulsion with ureteroscopy.
Study Procedure
Subjects underwent a screening ultrasound with the investigational device. Subjects then 
underwent the stone-pushing procedure by a sonographer and urologist. Raw ultrasound data 
and video was recorded. Subject position, stone location and motion were recorded. Stone 
motion was classified into 3 types for each Push: grade 1 reflected no motion, grade 2 
indicated that the stone moved within a confined space, such as a calyx, or rolled back to the 
same position, and grade 3 meant that the stone translated to a new location (> 3mm). A 
maximum of 40 Pushes was delivered. Subjects were asked to move to different positions 
and to briefly hold their breath to help with targeting.
Safety Assessment—Subjects completed a 10-point pain questionnaire before and after 
the study. Direct feedback on any sensations was obtained after the first 3 Pushes and as 
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noted thereafter. Research staff contacted the subjects weekly for 3 weeks and reviewed their 
medical charts over 90 days to assess for renal colic events, stone passage, or the need for 
additional intervention. An ultrasound was done after 4 weeks to rule out hydronephrosis or 
renal abnormalities.
Exceptions to Study Procedure—Subjects undergoing the investigational study during 
their ureteroscopic procedure were anesthetized and could not complete the pain 
questionnaire or provide feedback on any sensation felt during the procedure.
RESULTS
Subject Characteristics
15 subjects underwent ultrasonic propulsion, either awake without sedation (n=13) or 
anesthetized for simultaneous ureteroscopy (n=2) (Figure 1). Subject characteristics and 
baseline information are in Table 2. In total, 43 stone targets were visualized with ultrasound 
and targeted for stone pushing including: 24 lower pole, 10 interpolar, 5 upper pole, and 4 
renal pelvis targets.
Stone Motion
Figure 2 shows Push motion results for postlithotripsy subjects differentiated by target 
location and size, where fragments that moved are depicted in green. Figure 3 shows Push 
motion results for the de novo subjects. Table 3 highlights the results for each subject, 
grouped by those with postlithotripsy fragments and those with de novo stones, and Table 4 
summarizes results by management category.
Of the 43 targets, some level of motion was seen in 28 (65%), while 13 (30%) were 
displaced to a new location > 3mm (grade 3). Push motion results were consistent across 
stone locations and subject position, the most common being the lateral decubitus. Table 5 
displays the number of Pushes and the resultant stone-motion grade based on target location 
(a), patient position (b), and output voltage (c).
Repositioning Small Stones—Grade 3 stone motion was achieved with postlithotripsy 
fragments (Group 1) and small de novo stones known to be loose (Group 4). Grade 2 motion 
was achieved in 2 of the 3 small de novo observational subjects (Group 2); no grade 3 
motion occurred in these subjects.
Repositioning Large Stones—Stones > 5mm could be moved slightly (grade 2), but not 
displaced to a new location. The largest stone observed to move was 10mm. In the 2 subjects 
who underwent ultrasonic propulsion during ureteroscopy (Group 4), large stones in the 
renal pelvis (8mm and 12mm) were targeted but initially not moved. These stones were 
partially dusted with a laser until movement was achieved, which was estimated at 6mm. 
Skin-to-transducer distances were the greatest in these subjects (Table 3).
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Clearance of Small Stones
Stone clearance was monitored in postlithotripsy subjects (Group 1) and in subjects with 
small de novo stones under observation (Group 2). Four of six postlithotripsy subjects 
passed more than 30 stone fragments within days following the procedure (Figure 2). One 
subject passed 2 small stones immediately afterwards (Figure 4). For the remaining two 
subjects, one was 10 months postlithotripsy and had new stone formation. The other was 
noted to have a long infundibulum in which a stone was pushed part way through. This 
subject felt discomfort consistent with passing a small stone but did not see a stone pass, and 
follow-up imaging proved inconclusive.
No subjects in the small de novo Group 2 (n=3) reported passing a stone, although one 
subject was lost to follow-up and post procedure imaging in a second subject reported no 
stones.
For presurgical (Group 3) and perisurgical (Group 4) subjects, stone clearance was not 
applicable. However, subject #8 had a 3 mm stone in the proximal ureter at the time of 
ureteroscopy that may have been displaced from the lower pole during ultrasonic propulsion. 
Subject #11 had a 1 mm stone in the bladder at the time of surgery that also may have been 
displaced during ultrasonic propulsion. Although these two findings cannot be proven to be 
the result of ultrasonic propulsion, neither subject had a ureteral stone on preoperative 
imaging, or development of pain in the interim prior to their procedure, and neither had 
hydronephrosis or evidence of a ureteral stone at the time of ultrasonic propulsion.
Diagnostic Information
In at least 4 subjects in Group 1 (#6, 7, 9, 13), the clinical diagnostic report noted a single 
stone between 4-17mm, but ultrasonic propulsion revealed the single target was in fact a 
cluster of fragments small enough to pass. Figure 5 shows an example of the dispersion of a 
cluster of small stones.
Safety
No sensations were reported with the 50V Push. All subjects reported a warming of the skin 
from the transducer face with the 90V Push. Two subjects reported an internal sensation with 
1-3 of the 90V Pushes. The sensation was brief and not considered painful. Changing the 
probe angle eliminated the sensation. Two subjects reported an increase in baseline pain 
from the beginning to the end of the study, which they attributed to lying on the research 
table.
No unanticipated or serious adverse events were reported. No device-related adverse events 
were reported. No subject required medical intervention associated with ultrasonic 
propulsion.
DISCUSSION
This study reports several findings of the first-in-human clinical trial for ultrasonic 
propulsion of kidney stones; first, ultrasonic propulsion facilitated the passage of stone 
fragments. Residual fragments often result in unplanned stone events such as pain, 
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emergency room visits, or the need for an additional procedure.5-9 Unplanned visits were 
recently reported in 1 of 7 patients with average costs of $23,000-$32,000 after lithotripsy.4 
By facilitating the movement of these stone fragments, ultrasonic propulsion might decrease 
the need for future and costly unplanned care.
Second, ultrasonic propulsion can be performed in a clinic setting without sedation and 
without adverse events related to the procedure. Stone motion was achieved at both low 
power (50V) and high power (90V). Although the percentage of grade 2 and grade 3 stone 
motion was higher with 50V Pushes, larger stones, which proved more difficult to move, 
often lay at a greater distance from the transducer in the renal pelvis, and therefore received 
predominantly 90V Push attempts.
Third, some degree of movement was seen in both small and large stones. The ability to 
confirm both the presence of a stone within the collecting space and its attachment status 
with ureteroscopy enhanced the accuracy of this study. For the first 3 de novo subjects 
(Group 2), no direct visualization of the kidney was performed as opposed to the presurgical 
(Group 3) and perisurgical groups (Group 4), and thus we were unable to confirm if targets 
that did not move were indeed true targets, submucosal, or stones attached to the urothelium. 
In subjects that underwent a ureteroscopic procedure following the investigational study, we 
were able to confirm that stones unmoved were submucosal or attached.
Whether ultrasonic propulsion can dislodge a stone that is attached (e.g., to a Randall's 
plaque) remains unclear. Because many stones develop in this manner17, they spontaneously 
come loose at some point. Theoretically, loosely attached stones would be more likely to 
dislodge than firmly attached stones. One subject from Group 3, had two 7-8 mm stones that 
were targeted—one that moved with ultrasonic propulsion and one that did not. On 
ureteroscopy, a firmly attached stone and a separate stone in a calyx, that appeared to have 
been detached from a Randall's plaque, were detected. Currently, we have no way of 
knowing a priori which stones might or might not be attached and to what strength they are 
adherent.
Although we do not know the limit for stone movement based on size, with the current 
system we did achieve grade 2 motion in stones 7-10mm. The ability to move larger stones 
will depend on the location and depth. In this study, our goal of moving stones that were too 
large to pass was to investigate the potential application of moving an obstructing stone in 
the UPJ back into the kidney to relieve pain and obstruction. This could avoid an urgent 
temporizing procedure such as a ureteral stent or nephrostomy tube. In one subject, we were 
able to rotate an approximately 10mm stone within the renal pelvis. Although the movement 
was slight, this subject reported a decrease in pain. Even a small movement of a stone at the 
UPJ could provide relief for an individual or enable a stone to roll to a new location with 
change in body position.
Lastly, an unexpected finding of ultrasonic propulsion was its diagnostic capability. In at 
least 4 subjects, what appeared as a larger stone on imaging was shown to be a cluster of 
small passable stones (Figure 5). This is particularly important, as stone size is a major 
factor in management of urolithiasis.18,19 Most stones < 5 mm will pass spontaneously, 
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while stones ≥ 5 mm often require intervention.20,21 This result could have utility in 
determining indications for a primary or secondary lithotripsy procedure and may also help 
determine the endpoint of shockwave lithotripsy.
We acknowledge several limitations to this trial and barriers of this technology. It is unclear 
why certain stones do not move. Stone composition is not believed to be a significant factor 
based on in vitro studies and in this trial movement of calcium oxalate (monohydrate and 
dihydrate) as well as calcium phosphate (apatite and brushite) stones was achieved. One of 
the most important aspects of ultrasonic propulsion centers on finding the best alignment of 
the Push with, for example, the outflow (infundibulum) of a calyx. Gravity is also important, 
as is depth, and if there is not enough force to push a stone out of a calyx, it may fall back to 
the original location. The position of the patient can facilitate displacement of stones via 
gravity depending on the location of the stone and the renal anatomy. Other anatomical 
barriers include long, narrow, and steep infundibulopelvic angles, as these have also been 
described to decrease the passage of fragments after lithotripsy alone.22 A dilated collecting 
system is speculated to be beneficial since there is naturally more space for movement. 
Despite the barriers, it is believed that further and enhanced applications are possible with 
ongoing optimization of this technology.
CONCLUSION
This first-in-human feasibility study of ultrasonic propulsion was a success in accomplishing 
its primary and secondary goals. Further, in its current form, ultrasonic propulsion has a role 
in facilitating the passage of small kidney stones and can distinguish a cluster of small 
fragments from a larger stone.
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Figure 1. 
Study design for ultrasonic propulsion clinical trial. Group 1 = postlithotripsy fragments; 
Group 2 = de novo < 5 mm stones, Group 3 = de novo > 5 mm treated before surgery, and 
Group 4 = de novo stones treated during ureteroscopy. Grade 1 = no movement; Grade 2 = 
movement < 3 mm; Grade 3 = movement > 3 mm or to new location.
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Figure 2. 
Push motion results for subjects with postlithotripsy fragments. The number next to each 
target indicates the subject number. Different sized circles represent stone target sizes. Green 
represents stone movement and the green arrow highlights subjects that reported passing 
stones. The hash mark corresponds to a target that was identified as a single large stone on 
imaging but determined to be a cluster of small stones with ultrasonic propulsion.
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Figure 3. 
Push motion results for subjects with small and large de novo stones. The number next to 
each target indicates the subject number. Different sized circles represent stone target sizes. 
Green represents stone movement. The purple stone highlights a subject that experienced a 
decrease in pain with movement of a renal pelvis stone. Only stones < 5 mm were monitored 
for passage (subjects #1-3), of which there were none reported. Gray indicates stones treated 
with the investigational device that were reported as submucosal based on ureteroscopy.
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Figure 4. 
Stones passed by subject #4 (Group 1). (a) Shows the 2 stones that the subject passed in 
clinic immediately after the investigational procedure. (b) Shows an additional 14 stone 
fragments passed over the next couple days after the investigational procedure.
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Figure 5. 
Ultrasound images of the potential diagnostic role of ultrasonic propulsion. (a) A single 
large stone or possibly 2 medium-sized stones. Arrow indicates the direction of the Push. (b) 
Pushing of the stone revealed 6 or more small stone fragments.
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Table 1
Protocol inclusion and exclusion criteria
Inclusion Criteria Exclusion Criteria
• Patient of the UW urology clinic • Under 18 years of age
• At least one kidney stone or fragment • Nonechogenic stones (by ultrasound)
• Stone reported on clinic visit and observed on kidney-ureter-
bladder x-ray, computed tomography, or ultrasound
• Coagulation abnormality or taking blood thinners at clinically significant 
levels
• Stone confirmed on screening visit with investigational 
ultrasound device
• Mobility issues that prevented the subject from lying on the bed for 
extended periods or rolling between their abdomen, side, and back
• Individuals belonging to a vulnerable group (e.g. currently pregnant, 
prisoner, disabled)
UW, University of Washington
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Table 2
Subject characteristics and baseline assessments of kidney stones (N = 15 subjects; n=16 renal units)
VARIABLE RESULT
Age, mean (SD), years 56 (11)
BMI, mean (SD), kg/m2 29 (3)
Male, No. (%) 11 (73)
Skin-to-stone distance, mean (SD)
        By CT, cm 10.2 (2.0)
        By ultrasound, cm 7.1 (1.6)
Stone Size, range, mm 1-14
Stone location (side of kidney)
        Right 10
        Left 6
BMI, body mass index; CT, computed tomography; SD, standard deviation.
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Table 4
Summary of stone motion based on subject management groupA
Postlithotripsy (Group 1) De Novo (Group 2) Pre-URS (Group 3) Peri-URS (Group 4)
Subjects, n 6 3 4 2
Stones, range, n 5 to many 2–5 1–3 3
Stone size, mm ≤ 3 1–5 1–2, 7–14 1–2, 8–12
Pushes, mean (range) 39 (37–40) 30 (27–40) 23 (17–32) 28 (22–34)
% of Push w/ motionB
    Grade 1 35 75 81 58
    Grade 2 47 25 19 30
    Grade 3 18 0 0 12
Stones Passed, n 4 of 6 0 of 3 N/A N/A
N/A, not applicable; URS, ureteroscopy.
AGroup 1 = postlithotripsy fragments; Group 2 = de novo < 5 mm stones, Group 3 = de novo > 5 mm treated before surgery, and Group 4 = de 
novo stones treated during ureteroscopy.
BGrade 1 = no movement; grade 2 = movement < 3 mm; grade 3 = movement > 3 mm or new location.
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Table 5a
Motion grade results based on target location
Push Results by GradeA, n (%)
Target location 1 2 3
Lower pole 162 (46) 147 (42) 42 (12)
Mid pole 40 (71) 9 (16) 7 (13)
Upper pole 15 (52) 10 (34) 4 (14)
Renal pelvis 41 (76) 13 (24) 0 (0)
AGrade 1 = no movement; grade 2 = movement < 3 mm; grade 3 = movement ≥ 3 mm or new location.
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Table 5b
Motion grade results based on subject position
Push Results by GradeA, n (%)
Position 1 2 3
Prone 44 (60) 24 (32) 6 (8)
Side 137 (56) 87 (35) 23 (9)
Supine 42 (42) 46 (46) 12 (12)
AGrade 1 = no movement; Grade 2 = movement < 3 mm; Grade 3 = movement ≥ 3 mm or new location.
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Table 5c
Motion grade results based system output voltage
Push Results by GradeA, n (%)
Voltage, V 1 2 3
50 135 (47) 115 (40) 35 (12)
90 117 (61) 56 (29) 18 (9)
AGrade 1 = no movement; Grade 2 = movement < 3 mm; Grade 3 = movement ≥ 3 mm or new location.
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